PAXMAN announces that the state of Texas is preparing a bill proposing mandatory coverage of scalp cooling costs
PAXMAN announces that the state of Texas is preparing a bill that proposes mandatory coverage of scalp cooling costs in connection with chemotherapy by health care programs. The bill was addressed in a hearing before the House Committee on Insurance on April 16, and if it becomes legislation it would constitute an important step towards total cost coverage in the USA.
NOTICE OF THE ANNUAL GENERAL MEETING FOR PAXMAN AB
The shareholders of PAXMAN AB (publ) (”the Company”) are hereby invited to attend the Annual General Meeting on Thursday 23 May 2019 at 15:00 CET at meeting hall ”Amazonas”, NetPort, Biblioteksgatan 4, 374 35 KARLSHAMN. Registration will begin at 14:30 CET.
PAXMAN publishes newsletter on the company’s market approval in Japan
Today, PAXMAN publishes the April 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.
PAXMAN receives order for 20 scalp cooling systems to Japan two weeks after market approval
PAXMAN announces that the company has received an order for 20 scalp cooling systems to Japan from its distributor Century Medical. The systems will be installed at Tokyo Medical Center Hospital and Kyoto University Hospital, with deliveries starting in June.
PAXMAN receives market approval in Japan, will initiate comprehensive marketing activities in 2019
PAXMAN announces that the company has received a market approval (Shonin) in Japan for its market leading scalp cooling system that prevents chemotherapy-induced hair loss. The approval covers all solid tumours, and the company will initiate comprehensive market activities in Japan in 2019 together with its distributor Century Medical.
Paxman AB (publ): The NCCN Guidelines now recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer
PAXMAN today announce that the National Comprehensive Cancer Network® (NCCN®) has updated the Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) to include scalp cooling as a Category 2A recommendation to reduce the incidence of chemotherapy-induced alopecia for patients receiving chemotherapy.
Paxman AB (publ): PAXMAN publishes its year-end report January – December 2018
After a strong fourth quarter PAXMAN exceeded its turnover target for 2018
Paxman AB (publ): PAXMAN and University of Huddersfield invest 12 MSEK over 5 years into world’s first scalp cooling research and development centre
PAXMAN and the University of Huddersfield have signed a five-year research and collaboration agreement covering the PAXMAN Scalp Cooling Research Centre, a new multidisciplinary research group at the University of Huddersfield. The centre will focus on biological hair follicle research as well as developing innovative scalp cooling-related treatments and individual 3D-printed cooling caps.
Paxman AB (publ): PAXMAN publishes newsletter on its new CIPN indication and the double win at the EEF Future Manufacturing Awards
Today, PAXMAN publishes the February 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.
PAXMAN to develop medical cooling device to prevent nerve damage in chemotherapy patients with National University Hospital, Singapore
PAXMAN has signed a research collaboration agreement with National University Hospital, Singapore for the development of a portable cooling and compression device to prevent chemotherapy-induced peripheral neuropathy (nerve damage in hands and feet). The goal is to have a prototype ready for clinical studies in Q2 2020.